1. Immune cells and their derived microRNA-enriched extracellular vesicles in nonalcoholic fatty liver diseases
- Author
-
Liu Yang, Yawen Hao, Joost Boeckmans, Robim M. Rodrigues, Yong He, Faculty of Medicine and Pharmacy, Brussels Heritage Lab, Pharmaceutical and Pharmacological Sciences, and Experimental in vitro toxicology and dermato-cosmetology
- Subjects
Pharmacology ,Pharmacology, Toxicology and Pharmaceutics(all) ,inflammation ,NAFLD ,Macrophages ,Neutrophils/immunology ,Pharmacology (medical) ,Extracellular vesicles - Abstract
Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease worldwide. Despite extensive research and multiple clinical trials, there are still no FDA-approved therapies to treat the most severe forms of NAFLD. This is largely due to its complicated etiology and pathogenesis, which involves visceral obesity, insulin resistance, gut dysbiosis, etc. Although inflammation is generally believed to be one of the critical factors that drive the progression of simple steatosis to nonalcoholic steatohepatitis (NASH), the exact type of inflammation and how it contributes to NASH pathogenesis remain largely unknown. Liver inflammation is accompanied by the elevation of inflammatory mediators, including cytokines and chemokines and consequently intrahepatic infiltration of multiple types of immune cells. Recent studies revealed that extracellular vesicles (EVs) derived from inflammatory cells and hepatocytes play an important role in controlling liver inflammation during NASH. In this review, we highlight the roles of innate and adaptive immune cells and their microRNA-enriched EVs during NAFLD development and discuss potential drugs that target inflammatory pathways for the treatment of NAFLD.
- Published
- 2023